Our International Kidney Cancer Patient Charter was created to ensure that the more than one million people living with kidney cancer worldwide have access to the best available treatment, care, information and support. The Charter is based on a survey extended to 34 patient group leaders with a special interest in kidney cancer, located in 20 countries spread over 6 continents.
Cancer is one of the world’s most pressing health care challenges. On the whole, research progress from one year to the next is incremental, and true breakthroughs are exceptional. Nevertheless, every year brings new knowledge and insights that help direct further research and ultimately improve the outlook for patients with cancer. Clinical Cancer Advances 2017 highlights the most important clinical advances of the past year and previews where cancer science is headed. Advances highlighted
Berit Eberhardt represented IKCC at the European Society for Medical Oncology conference in Copenhagen, October 2016.
The theme of our booth was “An apple a day … keeps the doctor supporting patients with kidney cancer!”
The booth was very busy! Berit explained our current and planned projects, and chatted with visitors about clinical trials, 10 for IO, and our growing number of Affiliate groups worldwide.
7th International Kidney Cancer Coalition Conference
Warsaw, Poland 6th, 7th & 8th April 2017
Our seventh IKCC Conference for kidney cancer patient organisations will be held in Warsaw, Poland on 6th, 7th & 8th April 2017.
Our conference will bring together cancer patient group leaders from around the world to share best practices, exchange experiences and work together to improve the lives of kidney cancer patients wherever they live. Read more
The main goals of our conference will
submitted by Berit Eberhardt, Das Lebenshaus, Germany
I have found many of the tips in this article useful in Germany for our patients with kidney cancer — and others, not. You could modify this list for use in your own organisation.
As of December 2016, there are now TWO patient advocates on the NCI Renal Task Force.
The US National Cancer Institute’s Renal Task Force is an advisory group that involves the renal oncology community to address the design and prioritization of NCI funded phase 2 and phase 3 clinical trials in renal cell cancer.
Deb Maskens joins the Task Force as a Patient Advocate from the IKCC (International Kidney